Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
the exercise of 8,234 stock options and immediate sale of the resulting common shares, as disclosed in the SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$154,000 Post-transaction shares (direct) Post-transaction value (direct ownership) ~$6.36 million Transaction value and post-transaction value based on SEC Form 4 weighted average purchase price ($18.74). Key questions What is the nature of the transaction and how does the derivative context affect its interpretation? This trade reflects an option exercise with immediate sale, meaning Mazumdar converted 8,234 options into common shares and sold them in the open market; such transactions are typically used for liquidity and do not directly decrease long-term equity exposure, given the substantial remaining option pool. How does this transaction impact Mazumdar's overall direct and beneficial ownership? Direct common stock holdings decreased by 2.37% to 339,392
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.MarketBeat
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- BCAX's page on the SEC website